Syrris Celebrates its Most Successful Year to Date
News Feb 26, 2014
Syrris continues to lead the way with its batch reactor products and flow chemistry systems, increasing profits by over 50 % year-on-year.
This includes the top 20 pharmaceutical companies, leading universities and government institutes, plus companies working in fields such as food, flavor and fragrance, petrochemicals, nanoparticles and fine chemical synthesis.
Highlights of 2013 included a global series of workshops - enabling chemists to discover the advantages of flow and automated process chemistry - and the launch of an exclusive Customer Club, offering members easy access to a wide variety of select benefits and additional information.
Syrris also committed to a three-year, multi-million pound research and development program, part funded by European Union and Technology Strategy Board grants which were awarded in recognition of the Company’s ability to develop innovative, user-friendly and commercially successful products for chemists and chemical engineers.
The program will allow existing award-winning products, including Asia and Atlas reactors, to be further enhanced, and novel batch and flow chemistry products to be developed.
CEO Mike Hawes commented: “This is a really exciting time in Syrris’ history. Our most successful year ever has established Syrris as the market leader in flow chemistry products. The launch of our research and development program will deliver further world-class products offering the greatest control and ultimate ease of use to our customers, enabling a broader array of chemistry on a wider scale than ever before.”
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018